Align Technology Inc. (NASDAQ:ALGN) Q3 2020 Earnings Conference Call - Final Transcript

Thank you. [Operator Instructions] Our first question comes from the line of Nathan Rich with Goldman Sachs. Please proceed with your question.

Thanks and good afternoon. Joe and John, obviously, great to see the volumes come back so nicely. Sounds like the momentum continued in October. Could you maybe just kind of help us understand kind of the cadence of growth that you saw over the quarter? And any comments on how October has fared so far maybe relative to the type of case growth that you saw in 3Q?

Yeah, Nathan. Thanks for the question. Look, we just built through the quarter. Every month we saw actually continue to enhance momentum. And the short answer to your question is, we've seen that build in October also.

That's great. And Joe, obviously you kind of talked through in detail about what has kind of driven the stronger utilization that you've seen in the value of digital treatment. When you kind of take a step back and kind of think longer term, how is that kind of changed your outlook or influence your kind of multi-year outlook for kind of what you could see from this business over the next several years going forward?

Nathan, you know John and me, it's really long enough. I mean, we're incredibly enthusiastic about this business and bullish about this business. And you can see we're even more so as obviously we deliver the kind of results we have in 3Q. I think you always have to keep in mind two things here. One is, we're in a very volatile environment. We understand that. And we've done some things we feel that's really helped our doctors through this and made the company stronger coming out the other end.

But always remember, we're completely underpenetrated in this marketplace, right? We're still less than 10% penetrated from an orthodontic procedure standpoint, let alone those 300 million patients we talk about there they should receive orthodontic treatment, that aren't receiving orthodontic treatment. So let me -- we remain incredibly bullish with a digital format to be able to go after those patients and be able to continue to drive the growth of this business.

Thanks, Rich. Next question.

Okay. Thanks.

Next question, please.

Our next question comes from the line of Erin Wright with Credit Suisse. Please proceed with your question.

Q -- Erin Wright: Great. Thanks. So can you speak to some of the contributions from the recovery efforts in switching BRCA to MIR patients? Are you continuing to see those contributions and efforts into the fourth quarter? And do you think that will drive the Board's longer-term shift here? Do you have any indication based on the responses? I guess you've seen from practitioners, how sticky that is? Thanks. A -- Joseph Hogan: Well, it's -- overall -- it's Joe. I mean, overall it's pretty sticky when we buy the wires and brackets inventory back. And -- and then we introduced in the programs like Adapt and